Viriom

[Viriom @ViriomInc]

@MDPIOpenAccess

[Viriom @ViriomInc]

We've analyzed the risk/benefit profiles of the three leading oral antivirals for treatment of COVID-19 and here is what we found:
https://t.co/fbRh2UhP4y #covid19pandemic #covid #covid19research #covid19solutions #antivirals

[Viriom @ViriomInc]

Efficacy of Avifavir in #COVID19 patients has been confirmed in a multi-center open label post-marketing clinical study & presented at #CROI2021. Delivered to >1,000,000 patients in 17 countries in 2020, Avifavir anticipates a continuous adoption globally. https://t.co/c1feLmYQcu

[Viriom @ViriomInc]

Excited to start exploring the potential of delivering therapeutic doses of VM1500A over 4 and 8-week periods! #hiv #treatment #antiviral #clinicaltrials #phase2 #clinicalresearch #drugdevelopment https://t.co/18wfYF5Ig4

[Viriom @ViriomInc]

@Viriom is working with global health authorities to determine the efficacy and safety of Elpida and its other clinical candidates AV5080, AV5124 and AV5126 against #COVID19 - https://t.co/Kd6dtmgVUE…/17816949-viriom-donates-elpida-t…
#coronavirus #treatment #china #russia

[Viriom @ViriomInc]

Come out and meet us at CROI 2020! Email Iain Dukes at [email protected] to set up a meeting. https://t.co/CZRGWyEHRY #virus #HIV #conference #boston2020

[Viriom @ViriomInc]

Excited to be launching reproductive toxicity studies of Elpida®, supported by DAIDS (NIH) https://t.co/a6uqoCtO66 #hiv #hivaids #toxicity #nih #treatment #preclinical

[Viriom @ViriomInc]

Having opened a representative office in Beijing in 2017, we are now establishing an affiliate in Hong Kong and have just won a grant award to establish an affiliate in Mainland China! https://t.co/Rw47ND4l2D #China #affiliate #awardwinner #grants #HIV

[Viriom @ViriomInc]

Excited to announce that the ongoing Phase I studies of elsulfavirine (Elpida®) will now be supplemented by an NIH/NIAID and Division of AIDS collaboration with the Long-Acting/Extended Release Antiviral Resource Program (LEAP). https://t.co/0Tdn1LQzwh #NIH #AIDS #HIV

[Viriom @ViriomInc]

Viriom signed licensing agreement with P.T. Lloyd Pharma to help combat HIV drug resistance problem in #Indonesia. #pharma #drug #resistance #strategy #HIV #AIDS #licensing https://t.co/O2F3lCmjQF

[Viriom @ViriomInc]

Viriom files for market authorization in China - part of strategy to curb HIV epidemic in Greater China, Thailand & Indonesia. #hiv #epidemic #china #indonesia #thailand #developingmarkets #treatments https://t.co/AHeIDqhaGE

[Viriom @ViriomInc]

Happy to welcome our new CEO, Dr. Iain Dukes! #ceo
#HIV #treatment https://t.co/xlqojDjVoG

[Viriom @ViriomInc]

Our subsidiary in Beijing was just named the only foreign finalist of the 2018 Zhongguancun International Frontier Science and Technology Innovation Competition! https://t.co/n6k7hQSjwY #ChinaTech #science #technology #HIV #Competition

[Viriom @ViriomInc]

Excited to report the results from Phase 1b clinical trial of our once weekly oral formulation of a long acting HIV treatment! March 2019 #HIV #AIDS https://t.co/LM3OgnpaOu

[Viriom @ViriomInc]

Viriom Initiates Phase 1 Clinical Trial of Once Monthly Injectable HIV Treatment #clinicaltrials #clinicaltrial #phase #HIV #AIDS https://t.co/iFtzdhbJOG

[Viriom @ViriomInc]

The only emails you won't skip over in your mailbox! https://t.co/BdhJbZmSJy

[John Carroll @JohnCendpts]

You know you want to :)
Don’t miss my new daily biotech email from Endpoints — starts June 20. Sign up here: https://t.co/olg81hLSjg

[Viriom @ViriomInc]

Viriom to Present Results of Study on Long-Acting Formulations for Treatment and Prevention of HIV-1 Infections that could allow for once weekly or less frequent dosing. #HIV #AIDS https://t.co/EfscCJBD9O

[Viriom @ViriomInc]

@ViriomInc to Present Results of Pre-Clinical Pharmacokinetic Studies w/ Elsulfavirine @IASassociation 2017 https://t.co/5Au0rNbfPs

[Viriom @ViriomInc]

Viriom is testing its safer and more effective NNRTI, elsulfavirine https://t.co/QBSIuzQ53h #TreatmentForAll is on the horizon.

[Viriom @ViriomInc]

We just announced positive findings in #PhaseIIb study of Elpida® vs #Efavirenz in comb. with TDF/FTC at #Croi2017 https://t.co/yDo7wEHZeG